Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428338 | 0.84 | DGAT1 (0.36) | PDE10ADGAT1KLKB1 | |
| SCHEMBL31021830 | 0.84 | DGAT1 (0.41) | PDE10ADGAT1KLKB1BRD4 | |
| SCHEMBL614260 | 0.84 | DGAT1 (0.44) | PDE10ADGAT1KLKB1BRD4 | |
| SCHEMBL15315928 | 0.82 | PDE10A (0.39) | PDE10ADGAT1KLKB1 | |
| SCHEMBL31628936 | 0.82 | DGAT1 (0.35) | PDE10ADGAT1KLKB1 | |
| SCHEMBL4760581 | 0.81 | DGAT1 (0.34) | PDE10ADGAT1KLKB1 | |
| SCHEMBL3843505 | 0.81 | DGAT1 (0.34) | PDE10ADGAT1KLKB1 | |
| SCHEMBL4063219 | 0.81 | DGAT1 (0.55) | PDE10ADGAT1 | |
| SCHEMBL21465294 | 0.80 | DGAT1 (0.43) | PDE10ADGAT1KLKB1 | |
| SCHEMBL24736389 | 0.79 | DGAT1 (0.44) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675606-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2017-06-13 | — | — | US | disclosed |
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2015-11-19 | — | — | US | disclosed |
| US-9126972-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| EP-2709996-B1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI SA (FR) | 2015-06-24 | — | — | EP | disclosed |
| EP-2504338-B1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2709996-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2014-03-26 | — | — | EP | disclosed |
| US-8623893-B2 | Pyridino-pyridinone derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-03 | — | — | US | disclosed |
| WO-2012159959-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2012-11-29 | — | — | WO | disclosed |
| EP-2524915-A1 | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2504338-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011061458-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PDGFRB, FLT3, PDGFRA | PDE10A 2495/4885DGAT1 4815/4885KLKB1 1820/4885 |
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | KDR, FLT4, FLT1 | PDE10A 2200/4885DGAT1 4726/4885KLKB1 1070/4885 |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | PDE10A 3182/4885DGAT1 2615/4885KLKB1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.